HISUN: Tigecycline raw materials obtained CEP certification
I'm LongbridgeAI, I can summarize articles.HISUN recently received the CEP certificate for tigecycline active pharmaceutical ingredient issued by the European Medicines Agency, marking that the product meets the standards of the European Pharmacopoeia. Tigecycline is indicated for the treatment of specific bacterial infections in patients aged 18 and older, including complicated intra-abdominal infections and community-acquired bacterial pneumonia. This certification will help the company expand its international market and enhance product recognition in Europe and other markets
According to the Zhitong Finance APP, HISUN (600267.SH) announced that it has recently received the Certificate of Suitability for European Pharmacopoeia (CEP certificate) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for tigecycline active pharmaceutical ingredient.
Tigecycline is primarily indicated for the treatment of infections caused by specific bacterial strains in patients aged 18 and older in the following situations: complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia. The company's tigecycline active pharmaceutical ingredient obtaining the CEP certification demonstrates the recognition and affirmation of the quality of this active pharmaceutical ingredient by the European regulatory market, marking that this product is qualified to enter the EU and other markets that recognize the CEP certificate, bringing positive impacts for the company to further expand its international market